1. |
SHINNAR A E, BUTLER K L, PARK H J. Cathelicidin family of antimicrobial peptides:proteolytic processing and protease resistance[J]. Bioorganic chemistry, 2003, 31(6):425-436.
|
2. |
STEINSTRAESSER L, KOEHLER T, JACOBSEN F, et al. Host defense peptides in wound healing[J]. Molecular Medicine, 2008, 14(7-8):528-537.
|
3. |
MOLHOEK E M, DEN HERTOG A L, DE VRIES A M, et al. Structure-function relationship of the human antimicrobial peptide LL-37 and LL-37 fragments in the modulation of TLR responses[J]. Biol Chem, 2009, 390(4):295-303.
|
4. |
HENZLER WILDMAN K A, LEE D K, RAMAMOORTHY A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37[J]. Biochemistry, 2003, 42(21):6545-6558.
|
5. |
JONASCH E, HALUSKA F G. Interferon in oncological practice:review of interferon biology, clinical applications, and toxicities[J]. Oncologist, 2001, 6(1):34-55.
|
6. |
CUMMINS J M, KRAKOWKA G S, THOMPSON C G. Systemic effects of interferons after oral administration in animals and humans[J]. Am J Vet Res, 2005, 66(1):164-176.
|
7. |
OSBORN B L, OLSEN H S, NARDELLI B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-αfusion protein in cynomolgus monkeys[J]. J Pharmacol Exp Ther, 2002, 303(2):540-548.
|
8. |
RABHI-ESSAFI I, SADOK A, KHALAF N A. A strategy for high-level expression of soluble and functional human interferonαas a GST-fusion protein in E.coli[J]. Protein Engineering Design & Selection, 2007, 20(5):201-209.
|
9. |
WANG Yu-sen, YOUNGSTER S, GRACE M, et al. Structural and biological characterization of pegylated recombinant interferonα-2b and its therapeutic implications[J]. Adv Drug Deliv Rev, 2002, 54(4):547-570.
|
10. |
KURFURST M M. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after Sodium dodecyl sulfate-polyacry-lamide gel electrophoresis[J]. Anal Biochem, 1992, 200(2):244-248.
|
11. |
杨云霞, 朱玲, 王伯瑶, 等.人抗菌肽FALL-39突变分子的特性和抗菌功能的比较[J].华西药学杂志, 2006, 21(5):422-424.
|
12. |
LEE B K, KWON J S, KIM H J, et al. Solid-phase PEGylation of recombinant interferonα-2a for site-specific modification:process performance, characterization, and in vitro bioactivity[J]. Bioconjug Chem, 2007, 18(6):1728-1734.
|
13. |
ODAIMI M, JASSOUS I EI, RICHA A, et al. PhaseⅠ/Ⅱtrial of a novel regimem of GSM-CSF, IL-2 and pegylated interferon-alpha 2b (PEG-intron) for stageⅣmelanoma and renal cell carcinoma (RCC)[J]. Journal of Clinical Oncology, 2004, 22(14):7573-7579.
|
14. |
MAISER B, DISMER F, HUBBUCH J. Optimization of random PEGylation reactions by means of high throughput screening[J]. Biotechnol Bioeng, 2014, 111(1):104-114.
|